Skip to main content

Hypogonadotropic Hypogonadism

Endocrinology
1
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Endocrinology is a $1.4B mature market dominated by legacy products and characterized by significant patent cliff exposure in the near-term.

$1.4B marketMature→ Stable30 products15 companies

Key Trends

  • Two blockbusters (FORTEO, SYNTHROID) approaching LOE with $780M combined spend
  • Growth phase products (ORGOVYX, TYMLOS) entering peak revenue years through 2040
  • Heavy trial activity (625 total) concentrated in Phase 3 and Phase 4 studies indicating established disease focus

Career Verdict

Endocrinology offers stability and specialized expertise but limited growth upside; best suited for professionals comfortable in mature markets seeking deep disease knowledge rather than explosive market expansion.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1FORTEODeclining
$425M
Eli Lilly and Company·LOE_APPROACHING
#2SYNTHROIDDeclining
$355M
AbbVie·LOE_APPROACHING
#3ORGOVYXStable
$277M
#4TYMLOSStable
$198M
Radius Health·PEAK13.7yr

Drug Class Breakdown

Parathyroid Hormone Analogs
$425M(30%)

LOE approaching; potential for new mechanisms

Thyroid Replacement (T3/T4 synthesis)
$379M(27%)

Mature, multiple generics; limited differentiation

GnRH Receptor Antagonists
$278M(20%)

Growth trajectory through 2037

Growth Hormone Analogs (Somatropin)
$27M(2%)

Stable; multiple biosimilars in market

CYP11B1 Inhibitors (Cortisol management)
$45M(3%)

Emerging niche for rare endocrine disorders

Career Outlook

Stable

Endocrinology offers deep specialization and stable employment but limited growth trajectory; market maturity and patent cliff exposure create restructuring risk for legacy product teams at large pharma. Career advancement depends on niche expertise (rare endocrine disorders, bone metabolism) and willingness to work at smaller or specialist biotech firms where hiring is concentrated. Compensation is moderate relative to other therapeutic areas, with Medical Affairs and Clinical Operations commanding premiums.

Breaking In

Prioritize roles at Neurocrine Biosciences or other specialist firms over large pharma to gain endocrinology depth; seek Clinical Operations or IT positions for better compensation and career stability.

For Experienced Professionals

Experienced professionals should pursue Medical Affairs or senior Clinical Operations roles (highest salaries) or consider pivoting to emerging indications (GnRH antagonists in non-prostate oncology, novel PTH mechanisms) to avoid legacy product decline.

In-Demand Skills

Regulatory affairs (navigating complex endocrinology indications and biosimilar pathways)Health economics and market access (managing mature market competition)Clinical trial operations (Phase 3/4 expertise given trial distribution)Real-world evidence and outcomes research (post-approval monitoring of legacy products)

Best For

Medical Science Liaison (strong compensation, focused disease education)Clinical Operations Manager (11% of roles, $210K avg)Regulatory Affairs Specialist (managing LOE transitions and generic competition)Market Access Analyst (managing pricing pressure on thyroid and bone products)

Hiring Landscape

$115K-$359K

Endocrinology hiring is concentrated at specialist biotech firms (Neurocrine: 126 jobs, 93% of available positions) rather than large pharma, indicating a niche market dynamic. IT roles dominate openings (51 jobs, $201K avg) followed by R&D (21 jobs, $120K avg), suggesting company-level digitalization and data infrastructure needs. Compensation ranges widely ($115K-$359K), with Medical Affairs offering premium salaries ($359K) but minimal openings (6 jobs).

135
Open Roles
3
Companies Hiring
5
Departments

Top Hiring Companies

3Stable

By Department

IT(38%)
$201K
Research & Development(16%)
$120K
Commercial(13%)
$115K
Clinical Operations(11%)
$210K
Medical Affairs(4%)
$359K

Limited total opportunity (135 jobs) concentrated at one biotech firm signals a tight job market; IT and Clinical Operations offer best compensation, but specialized endocrinology roles are scarce.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
GnRHPhase 21 trial
Active Trials
NCT00383656Unknown270Est. Sep 2020
Mereo BioPharma
Mereo BioPharmaUK - London
2 programs
BGS649PHASE_21 trial
BGS649PHASE_21 trial
Active Trials
NCT02730169Completed271Est. May 2018
NCT02908074Completed143Est. Nov 2018
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
5-day controlled metabolic dietary intakeN/A1 trial
Active Trials
NCT05808647Unknown25Est. Jan 2025
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Gonadotropin-releasing HormoneN/A1 trial
Active Trials
NCT02705014Unknown20Est. Aug 2017
Takeda
TakedaTOKYO, Japan
1 program
TAK-448PHASE_21 trial
Active Trials
NCT02369796Terminated15Est. Nov 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mereo BioPharmaBGS649
Mereo BioPharmaBGS649
TakedaTAK-448
Human BioSciencesGnRH
Colorado Therapeutics5-day controlled metabolic dietary intake
UNION therapeuticsGonadotropin-releasing Hormone

Clinical Trials (6)

Total enrollment: 744 patients across 6 trials

A 6 Month Safety Extension Study of MBGS205

Start: Nov 2016Est. completion: Nov 2018143 patients
Phase 2Completed

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Start: May 2016Est. completion: May 2018271 patients
Phase 2Completed

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

Start: Feb 2015Est. completion: Nov 201515 patients
Phase 2Terminated

Pulsatile GnRH in Anovulatory Infertility

Start: Jan 1989Est. completion: Sep 2020270 patients
Phase 2Unknown
NCT05808647Colorado Therapeutics5-day controlled metabolic dietary intake

Low Energy Availability and Pituitary Function (LEAP Study)

Start: Apr 2023Est. completion: Jan 202525 patients
N/AUnknown
NCT02705014UNION therapeuticsGonadotropin-releasing Hormone

Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome

Start: Jan 2016Est. completion: Aug 201720 patients
N/AUnknown

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.